Skip to main content
Top
Published in: Infection 2/2016

01-04-2016 | Case Report

Acne inversa complicated by Actinomyces neuii

Authors: Jakob Nedomansky, Doris Weiss, Birgit Willinger, Stefanie Nickl, Christoph Steininger

Published in: Infection | Issue 2/2016

Login to get access

Abstract

Introduction

Acne inversa (AI) is a chronic and recurrent inflammatory skin disease. It occurs in intertriginous areas of the skin and causes pain, drainage, malodor and scar formation. While supposedly caused by an autoimmune reaction, bacterial superinfection is a secondary event in the disease process.

Methods

A unique case of a 43-year-old male patient suffering from a recurring AI lesion in the left axilla was retrospectively analysed.

Results

A swab revealed Actinomyces neuii as the only agent growing in the lesion. The patient was then treated with Amoxicillin/Clavulanic Acid 3 × 1 g until he was cleared for surgical excision. The intraoperative swab was negative for A. neuii. Antibiotics were prescribed for another 4 weeks and the patient has remained relapse free for more than 12 months now.

Conclusion

Primary cutaneous Actinomycosis is a rare entity and the combination of AI and Actinomycosis has never been reported before. Failure to detect superinfections of AI lesions with slow-growing pathogens like Actinomyces spp. might contribute to high recurrence rates after immunosuppressive therapy of AI. The present case underlines the potentially multifactorial pathogenesis of the disease and the importance of considering and treating potential infections before initiating immunosuppressive regimens for AI patients.
Literature
1.
2.
3.
go back to reference von Laffert M, Helmbold P, Wohlrab J, Fiedler E, Stadie V, Marsch WC. Hidradenitis suppurativa (acne inversa): early inflammatory events at terminal follicles and at interfollicular epidermis. Exp Dermatol. 2010;19(6):533–7.CrossRef von Laffert M, Helmbold P, Wohlrab J, Fiedler E, Stadie V, Marsch WC. Hidradenitis suppurativa (acne inversa): early inflammatory events at terminal follicles and at interfollicular epidermis. Exp Dermatol. 2010;19(6):533–7.CrossRef
4.
go back to reference van der Zee HH, Laman JD, Boer J, Prens EP. Hidradenitis suppurativa: viewpoint on clinical phenotyping, pathogenesis and novel treatments. Exp Dermatol. 2012;21(10):735–9.PubMed van der Zee HH, Laman JD, Boer J, Prens EP. Hidradenitis suppurativa: viewpoint on clinical phenotyping, pathogenesis and novel treatments. Exp Dermatol. 2012;21(10):735–9.PubMed
5.
go back to reference Sartorius K, Killasli H, Oprica C, Sullivan A, Lapins J. Bacteriology of hidradenitis suppurativa exacerbations and deep tissue cultures obtained during carbon dioxide laser treatment. Br J Dermatol. 2012;166(4):879–83.CrossRefPubMed Sartorius K, Killasli H, Oprica C, Sullivan A, Lapins J. Bacteriology of hidradenitis suppurativa exacerbations and deep tissue cultures obtained during carbon dioxide laser treatment. Br J Dermatol. 2012;166(4):879–83.CrossRefPubMed
6.
go back to reference Valour F, Senechal A, Dupieux C, Karsenty J, Lustig S, Breton P, et al. Actinomycosis: etiology, clinical features, diagnosis, treatment, and management. Infect Drug Res. 2014;7:183–97. Valour F, Senechal A, Dupieux C, Karsenty J, Lustig S, Breton P, et al. Actinomycosis: etiology, clinical features, diagnosis, treatment, and management. Infect Drug Res. 2014;7:183–97.
7.
go back to reference Gomez-Garces JL, Burillo A, Gil Y, Saez-Nieto JA. Soft tissue infections caused by Actinomyces neuii, a rare pathogen. J Clin Microbiol. 2010;48(4):1508–9.CrossRefPubMedPubMedCentral Gomez-Garces JL, Burillo A, Gil Y, Saez-Nieto JA. Soft tissue infections caused by Actinomyces neuii, a rare pathogen. J Clin Microbiol. 2010;48(4):1508–9.CrossRefPubMedPubMedCentral
8.
go back to reference Bennhoff DF. Actinomycosis: diagnostic and therapeutic considerations and a review of 32 cases. Laryngoscope. 1984;94(9):1198–217.CrossRefPubMed Bennhoff DF. Actinomycosis: diagnostic and therapeutic considerations and a review of 32 cases. Laryngoscope. 1984;94(9):1198–217.CrossRefPubMed
9.
go back to reference Blok JL, van Hattem S, Jonkman MF, Horvath B. Systemic therapy with immunosuppressive agents and retinoids in hidradenitis suppurativa: a systematic review. Br J Dermatol. 2013;168(2):243–52.CrossRefPubMed Blok JL, van Hattem S, Jonkman MF, Horvath B. Systemic therapy with immunosuppressive agents and retinoids in hidradenitis suppurativa: a systematic review. Br J Dermatol. 2013;168(2):243–52.CrossRefPubMed
10.
go back to reference Breton AL, Lamblin G, Pariset C, Jullien D. Cutaneous actinomycosis associated with anti-TNF-alpha therapy: report of two cases. Dermatology. 2014;228(2):112–4.CrossRefPubMed Breton AL, Lamblin G, Pariset C, Jullien D. Cutaneous actinomycosis associated with anti-TNF-alpha therapy: report of two cases. Dermatology. 2014;228(2):112–4.CrossRefPubMed
Metadata
Title
Acne inversa complicated by Actinomyces neuii
Authors
Jakob Nedomansky
Doris Weiss
Birgit Willinger
Stefanie Nickl
Christoph Steininger
Publication date
01-04-2016
Publisher
Springer Berlin Heidelberg
Published in
Infection / Issue 2/2016
Print ISSN: 0300-8126
Electronic ISSN: 1439-0973
DOI
https://doi.org/10.1007/s15010-015-0814-6

Other articles of this Issue 2/2016

Infection 2/2016 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine